Market Closed -
Nasdaq
02:00:01 15/05/2024 am IST
|
5-day change
|
1st Jan Change
|
0.2897
USD
|
-0.48%
|
|
-4.07%
|
-86.33%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
12.63
|
25.23
|
29.17
|
12.86
|
17.92
|
3.212
|
-
|
Enterprise Value (EV)
1 |
12.63
|
25.23
|
29.17
|
12.86
|
17.92
|
3.212
|
3.212
|
P/E ratio
|
-0.72
x
|
-1.19
x
|
-2.47
x
|
-0.89
x
|
-1.34
x
|
-0.27
x
|
-0.28
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
16.1
x
|
3.21
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
16.1
x
|
3.21
x
|
EV / EBITDA
|
-11,73,307
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
2.73
x
|
1.79
x
|
2.38
x
|
-0.63
x
|
-0.21
x
|
Nbr of stocks (in thousands)
|
376
|
1,682
|
2,108
|
3,159
|
8,455
|
11,036
|
-
|
Reference price
2 |
33.60
|
15.00
|
13.84
|
4.070
|
2.120
|
0.2897
|
0.2897
|
Announcement Date
|
26/03/20
|
25/03/21
|
30/03/22
|
14/03/23
|
28/03/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
0.2
|
1
|
EBITDA
|
-10.76
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-10.84
|
-11.5
|
-11.5
|
-13.16
|
-10.52
|
-11.9
|
-12
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-5,950%
|
-1,200%
|
Earnings before Tax (EBT)
1 |
-13.31
|
-11.73
|
-11.23
|
-13.18
|
-10.06
|
-11.9
|
-12
|
Net income
1 |
-17.53
|
-12.12
|
-11.35
|
-13.18
|
-10.06
|
-11.9
|
-12
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-5,950%
|
-1,200%
|
EPS
2 |
-46.80
|
-12.60
|
-5.600
|
-4.560
|
-1.580
|
-1.060
|
-1.040
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
26/03/20
|
25/03/21
|
30/03/22
|
14/03/23
|
28/03/24
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.1
|
0.1
|
0.1
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-2.651
|
-3.072
|
-2.855
|
-3.572
|
-3.417
|
-3.313
|
-2.939
|
-2.995
|
-3.129
|
-1.5
|
-3
|
-3
|
-3
|
-3
|
-3.1
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,000%
|
-3,000%
|
-3,100%
|
Earnings before Tax (EBT)
1 |
-2.658
|
-3.105
|
-2.858
|
-3.591
|
-3.44
|
-3.29
|
-2.943
|
-2.557
|
-3.101
|
-1.5
|
-3
|
-3
|
-3
|
-3
|
-3.1
|
Net income
1 |
-2.658
|
-3.105
|
-2.858
|
-3.591
|
-3.44
|
-3.29
|
-2.943
|
-2.557
|
-3.101
|
-1.5
|
-3
|
-3
|
-3
|
-3
|
-3.1
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,000%
|
-3,000%
|
-3,100%
|
EPS
2 |
-1.200
|
-1.400
|
-1.400
|
-1.200
|
-1.000
|
-0.9600
|
-0.9300
|
-0.4300
|
-0.4000
|
-0.1700
|
-0.2700
|
-0.2700
|
-0.2600
|
-0.2600
|
-0.2700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/11/21
|
30/03/22
|
12/05/22
|
15/08/22
|
14/11/22
|
14/03/23
|
15/05/23
|
14/08/23
|
14/11/23
|
28/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
5.070
|
2.270
|
0.8900
|
-0.4600
|
-1.380
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.04
|
-
|
0.05
|
0.2
|
0.03
|
-
|
0.1
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
10%
|
Announcement Date
|
26/03/20
|
25/03/21
|
30/03/22
|
14/03/23
|
28/03/24
|
-
|
-
|
Last Close Price
0.2897
USD Average target price
10
USD Spread / Average Target +3,351.85% Consensus |
1st Jan change
|
Capi.
|
---|
| -86.33% | 3.21M | | +29.03% | 48.16B | | -0.10% | 41.73B | | +43.45% | 41.03B | | -5.26% | 28.77B | | +11.48% | 25.59B | | -22.74% | 18.96B | | +9.06% | 12.92B | | +30.01% | 12.03B | | -1.51% | 11.77B |
Other Biotechnology & Medical Research
|